Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 12/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862940 | 0.84 | CHRNB2 (0.69) | PRMT6CHRNB2CHRNA4CARM1PRMT8 | |
| SCHEMBL1690457 | 0.77 | CYP2A6 (0.68) | PRMT6CYP2A6EPHX2CHRNA7ALDH1A1 | |
| SCHEMBL5115281 | 0.75 | CHRNB2 (0.65) | PRMT6CHRNB2CHRNA4CARM1PRMT8 | |
| SCHEMBL16118323 | 0.74 | CYP2A6 (0.56) | PRMT6CHRNB2CHRNA4CYP2A6EPHX2 | |
| SCHEMBL16125893 | 0.72 | MAPK1 (0.60) | PRMT6CARM1PRMT8CYP2A6ALDH1A1 | |
| SCHEMBL13066714 | 0.71 | CYP2A6 (0.56) | PRMT6CYP2A6EPHX2ALDH1A1CYP1A2 | |
| SCHEMBL844549 | 0.71 | MKNK1 (0.68) | PRMT6CYP2A6EPHX2ALDH1A1CYP1A2 | |
| SCHEMBL844599 | 0.71 | CYP2A6 (0.56) | PRMT6CYP2A6EPHX2ALDH1A1CYP1A2 | |
| SCHEMBL4869525 | 0.70 | CYP2A6 (0.50) | PRMT6CYP2A6EPHX2ALDH1A1CYP1A2 | |
| SCHEMBL10028665 | 0.69 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | PRMT6 3551/4885CHRNB2 4844/4885CHRNA4 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.